Some patients notice reduced appetite within the first 1 to 2 weeks, even at the starting dose of 0.25 mg
While the specific risk of gallstone formation is not applicable to patients who have already undergone cholecystectomy, other biliary tract complications remain theoretically possible
Lyons DJ, Hellysaz A, Broberger C
Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial
What this means for you: Current evidence strongly suggests Mounjaro doesnt increase cancer risk in the short to medium term, and it may reduce risk through weight loss and metabolic benefits
It gives you time to practice new behaviors without fighting constant hunger and cravings